Literature DB >> 8345568

The pharmacokinetics of flunixin meglumine in the sheep.

E M Welsh1, Q A McKellar, A M Nolan.   

Abstract

Flunixin meglumine was administered intravenously and intramuscularly in sheep and the pharmacokinetics of the drug studied. Plasma concentrations of flunixin were measured by high performance liquid chromatography. The decline in plasma flunixin concentration with time was best fitted by a triexponential equation. The pharmacokinetics following intravenous administration of 1.0 mg/kg indicate that flunixin has a rapid distribution half-life (t1/2 pi = 2.3 min), a slow body clearance rate (Clb = 0.6 ml/kg/min) and an elimination half-life of 229 min. Similarly, at 2.0 mg/kg, flunixin is rapidly distributed from the plasma, t1/2 pi = 2.7 min, has a slow body clearance rate (Clb = 0.7 ml/kg/min) and an elimination half-life of 205 min. Following intramuscular injection flunixin is rapidly and well absorbed from the injection site. It had a mean maximum concentration (Cmax) of > or = 5.9 micrograms/ml when administered at a dose rate of 1.1 mg/kg, and a relative bioavailability of 70%. Plasma concentrations increase proportionally to dose over the range 1.1 mg/kg-2.2 mg/kg when administered by the intramuscular route.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345568     DOI: 10.1111/j.1365-2885.1993.tb00162.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  8 in total

1.  Preliminary pharmacokinetic and pharmacodynamic studies on flunixin meglumine in donkeys.

Authors:  Z Cheng; Q McKellar; A Nolan; P Lees
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

2.  A preclinical large-animal model for the assessment of critical-size load-bearing bone defect reconstruction.

Authors:  David S Sparks; Siamak Saifzadeh; Flavia Medeiros Savi; Constantin E Dlaska; Arne Berner; Jan Henkel; Johannes C Reichert; Martin Wullschleger; Jiongyu Ren; Amaia Cipitria; Jacqui A McGovern; Roland Steck; Michael Wagels; Maria Ann Woodruff; Michael A Schuetz; Dietmar W Hutmacher
Journal:  Nat Protoc       Date:  2020-02-14       Impact factor: 13.491

3.  Voltammetric Determination of Flunixin on Molecularly Imprinted Polypyrrole Modified Glassy Carbon Electrode.

Authors:  Abd-Elgawad Radi; Nadia Abd El-Ghany; Tarek Wahdan
Journal:  J Anal Methods Chem       Date:  2016-05-08       Impact factor: 2.193

4.  Palatability and pharmacokinetics of flunixin when administered to sheep through feed.

Authors:  Danila Marini; Joe Pippia; Ian G Colditz; Geoff N Hinch; Carol J Petherick; Caroline Lee
Journal:  PeerJ       Date:  2016-03-14       Impact factor: 2.984

5.  A study to assess the correlation between plasma, oral fluid and urine concentrations of flunixin meglumine with the tissue residue depletion profile in finishing-age swine.

Authors:  Jessica L Bates; Locke A Karriker; Suzanne M Rajewski; Zhoumeng Lin; Ronette Gehring; Mengjie Li; Jim E Riviere; Johann F Coetzee
Journal:  BMC Vet Res       Date:  2020-06-22       Impact factor: 2.741

6.  Analgesic Comparison of Flunixin Meglumine or Meloxicam for Soft-Tissue Surgery in Sheep: A Pilot Study.

Authors:  Abbie V Viscardi; Emily J Reppert; Michael D Kleinhenz; Payton Wise; Zhoumeng Lin; Shawnee Montgomery; Hayley Daniell; Andrew Curtis; Miriam Martin; Johann F Coetzee
Journal:  Animals (Basel)       Date:  2021-02-06       Impact factor: 2.752

7.  Pharmacokinetics and pharmacodynamic effects of flunixin after intravenous, intramuscular and oral administration to dairy goats.

Authors:  K Königsson; K Törneke; I V Engeland; K Odensvik; H Kindahl
Journal:  Acta Vet Scand       Date:  2003       Impact factor: 1.695

8.  Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration.

Authors:  Monique D Pairis-Garcia; Locke A Karriker; Anna K Johnson; Butch Kukanich; Larry Wulf; Suzanne Sander; Suzanne T Millman; Kenneth J Stalder; Johann F Coetzee
Journal:  BMC Vet Res       Date:  2013-08-13       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.